Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

42.34
-0.7701-1.79%
Post-market: 42.350.0101+0.02%16:10 EDT
Volume:2K
Turnover:64.58K
Market Cap:31.75M
PE:- -
High:42.35
Open:42.35
Low:42.34
Close:43.11
52wk High:43.11
52wk Low:29.32
Shares:750.00K
Float Shares:750.00K
Volume Ratio:2.57
T/O Rate:0.20%
Dividend:0.14
Dividend Rate:0.34%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Guardant Health Shares Climb Following Outlook Raise

Dow Jones
·
Jul 31

RBC Raises Price Target on Guardant Health to $200 From $185, Keeps Outperform Rating

MT Newswires Live
·
Jul 31

Guardant Health is Maintained at Buy by BTIG

Dow Jones
·
Jul 31

Guardant Health Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Guardant Health Inc : RBC Raises Target Price to $200 from $185

THOMSON REUTERS
·
Jul 31

Guardant Health files automatic mixed securities shelf

TIPRANKS
·
Jul 31

Guardant Health Inc Files for Mixed Shelf Offering; Size not Disclosed- SEC Filing

THOMSON REUTERS
·
Jul 31

Guardant Health Q2 Adjusted Loss Narrows, Revenue Rises

MT Newswires Live
·
Jul 31

Veracyte Q2 Revenue Rises on Decipher and Afirma Test Sales

Reuters
·
Jul 31

Fulgent Genetics Q2 Revenue Rises 20% Sequentially, Sees Billing System Transition Delay

Reuters
·
Jul 31

CareDx Q2 Revenue Beats Estimates; Outlook Lifted

Reuters
·
Jul 31

Guardant Health Q2 Adj. EPS $(0.42) Misses $(0.41) Estimate, Sales $334.978M Beat $314.226M Estimate

Benzinga Earnings
·
Jul 31

Guardant Health Q2 Adjusted EPS USD -0.42 Vs. IBES Estimate USD -0.41

Reuters
·
Jul 31

Guardant Health - Sees 2026 Free Cash Flow Burn $195-$205 Mln

THOMSON REUTERS
·
Jul 31

Adaptive Biotechnologies is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 30

Asymchem Laboratories Injects RMB 1.05 Billion into Shanghai Subsidiary

Stock News
·
Jul 30

Natera Schedules Second-quarter Results Conference Call

Reuters
·
Jul 30

Adaptive Biotechnologies price target raised to $25 from $24 at BTIG

TIPRANKS
·
Jul 30

Adaptive Biotechnologies Corp : Morgan Stanley Raises Target Price to $22 from $20

THOMSON REUTERS
·
Jul 30

Metabolic disorder biotech Vogenx targets $75 million IPO at $11-$13 per share

Stock News
·
Jul 30